Search

Displaying results 5081 - 5090 of 10000 in total
  1. Drug

    anti-alpha5Beta1-integrin antibody

    go.drugbank.com/drugs/DB05870
    Experimental

    Integrins are important adhesion molecules that regulate tumor and endothelial cell survival, proliferation and migration. The integrin alpha5beta1 has been shown to play a critical role during angiogenesis. anti-alpha5beta1 integrin ant...

  2. Drug

    NCX 1015

    go.drugbank.com/drugs/DB05825
    Experimental

    NCX 1015 is nitric oxide-releasing derivative of prednisolone developed for the treatment of inflammatory bowel disease (IBD) by NicOx SA.

  3. Drug

    CPG 10101

    go.drugbank.com/drugs/DB05530
    Investigational

    CPG 10101 is a synthetic oligodeoxynucleotide (ODN) in clinical trials. … It is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV.

  4. Drug

    Cixutumumab

    go.drugbank.com/drugs/DB12250
    Investigational

    Cixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of tumour types. … Cixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate.

  5. Drug

    RAPA-501-Allo

    go.drugbank.com/drugs/DB15890
    Investigational

    RAPA-501-ALLO is composed of T-cells extracted from healthy volunteers; these cells are then reprogrammed _ex vivo_ in a process that involves de-differentiation and re-differentiation.[L16483]

  6. Drug

    Rosmarinic acid

    go.drugbank.com/drugs/DB16865
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Methyl undecenoyl leucinate

    go.drugbank.com/drugs/DB11272
    Approved

    Methyl undecenoyl leucinate is an active ingredient in whitening creams. … It is an α-MSH antagonist that inhibits melanin synthesis and tyrosinase activity and reduces expression of various melanogenic genes.

  8. Drug

    VB2-011

    go.drugbank.com/drugs/DB05411
    Experimental

    VB2-011 is an antibody developed as an anti-cancer treatment. According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma.

  9. Drug

    alpha-Conotoxin VC 1.1

    go.drugbank.com/drugs/DB05724
    Experimental

  10. Drug

    Dibekacin

    go.drugbank.com/drugs/DB13270
    Approved

    Dibekacin is an aminoglycoside antibiotic marketed in Japan [L5623].